Inhibition of GPR44 has been well studied in inflammatory processes responsible for allergy and asthma [70], leading to the development of numerous GPR44 antagonists for the treatment of asthma and other allergic diseases, some of them even reaching late clinical phase drug development [71]. This evidence concerns the gene PTGDR2 and allergic disease.